Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.24
- Piotroski Score 3.00
- Grade Buy
- Symbol (AGEN)
- Company Agenus Inc.
- Price $4.14
- Changes Percentage (1.97%)
- Change $0.08
- Day Low $3.98
- Day High $4.17
- Year High $19.69
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $9.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $11.60
- Trailing P/E Ratio 1.43
- Forward P/E Ratio 1.43
- P/E Growth 1.43
- Net Income $-245,761,000
Income Statement
Quarterly
Annual
Latest News of AGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Mets free-agent outlook: Should they bring back Jesse Winker or J.D. Martinez?
Jesse Winker's impact on the Mets with his postseason performance and versatility is noted. Despite his impressive stats, his future with the team remains uncertain. On the other hand, J.D....
By The New York Times | 9 hours ago -
Blue Jays free agent fits: Which hitters can help Toronto's stalling offence?
The Toronto Blue Jays are looking to boost their offense this offseason, particularly in adding power hitters. Potential free-agent targets range from superstars like Soto to complementary additions l...
By The New York Times | 10 hours ago -
Are payment deferrals the new big thing in NHL contracts? What execs, agents say
NHL players like Jake McCabe are increasingly using deferred salary contracts to maximize earnings and provide teams with cap flexibility. While this trend may not become widespread due to player pref...
By The New York Times | 10 hours ago
